{"product_id":"fish-vaccination-hardback-9780470674551","title":"Fish Vaccination (Hardback) 9780470674550","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eFish Vaccination\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eRoar Gudding (Edited by), R Gudding (Author), Atle Lillehaug (Edited by), Oystein Evensen (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470674550, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 18 April 2014\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e408 pages\u003cbr\u003e25.2 x 17.8 x 2.3 cm, 0.943 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e“That notwithstanding, this book is an essential resource for veterinarians, aquaculturists, and fish biologists interested in disease prevention and biosecurity, improvement of aquaculture production, and the enhancement of the health and welfare of captive fish populations or for anyone interested in fish vaccinology.”  (\u003ci\u003eJournal of the American Veterinary Medical Association\u003c\/i\u003e, 15 September 2014)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eFish farming, in seawater and in freshwater, in cages, tanks or ponds, makes an ever-increasing and significant contribution to the production of aquatic food in many regions of the world. During the last few decades there has been significant progress and expansion in the aquaculture sector, characterized by intensified production and the exploitation of many new species.\u003cbr\u003e \u003cbr\u003e Aquaculture must be a sustainable bio-production, environmentally as well as economically. Disease prevention in order to reduce losses, and the use of antimicrobials is crucial in this perspective. Vaccination has, in a few years, become the most important method for disease prevention in aquaculture, and effective prophylaxis based on stimulation of the immune system of the fish is essential for further development of the industry.\u003cbr\u003e \u003cbr\u003e This book provides general information about disease prevention in fish by vaccination, as well as specific descriptions of the correct use of vaccines against the most important bacterial and viral infectious diseases of aquatic animals. The book is written by some of the world’s leading experts in the subject, drawn from many countries where aquaculture is a significant and expanding part of the economy.\u003cbr\u003e \u003ci\u003e\u003cbr\u003e Fish Vaccination\u003c\/i\u003e is an encyclopedia of fish vaccinology for every present and future aquaculturist. Professionals in the aquaculture sector, including fish veterinarians and fish biologists, within the industry, in scientific institutions and regulatory authorities will all find a huge wealth of commercially important knowledge within this book. Libraries in all universities where aquaculture, biological and veterinary sciences are studied and taught should have copies of this important book on their shelves.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eContributors xv\u003c\/p\u003e \u003cp\u003ePreface xix\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 The History of Fish Vaccination 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRoar Gudding and Thomas Goodrich\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 1\u003c\/p\u003e \u003cp\u003e1.2 Aquaculture 2\u003c\/p\u003e \u003cp\u003e1.3 Immunology 2\u003c\/p\u003e \u003cp\u003e1.4 Disease Prevention 3\u003c\/p\u003e \u003cp\u003e1.5 Scientific Production – Reviews and Conferences 4\u003c\/p\u003e \u003cp\u003e1.6 Successes and Failures 7\u003c\/p\u003e \u003cp\u003e1.7 The Pioneers 7\u003c\/p\u003e \u003cp\u003e1.8 Concluding Remarks 8\u003c\/p\u003e \u003cp\u003eReferences 9\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Vaccination as a Preventive Measure 12\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRoar Gudding\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 12\u003c\/p\u003e \u003cp\u003e2.2 Biosecurity and Vaccination 13\u003c\/p\u003e \u003cp\u003e2.3 Use of Vaccination in Aquaculture 15\u003c\/p\u003e \u003cp\u003e2.4 Vaccination Against Different Diseases 16\u003c\/p\u003e \u003cp\u003e2.5 Herd Immunity 17\u003c\/p\u003e \u003cp\u003e2.6 Economic Considerations 18\u003c\/p\u003e \u003cp\u003e2.7 Risk Assessment 18\u003c\/p\u003e \u003cp\u003e2.8 The Market for Fish Vaccines 19\u003c\/p\u003e \u003cp\u003eReferences 20\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Non-replicating Vaccines 22\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eHetron Mweemba Munang’andu, Stephen Mutoloki and Øystein Evensen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 22\u003c\/p\u003e \u003cp\u003e3.2 Classification 22\u003c\/p\u003e \u003cp\u003e3.3 Inactivated Vaccines – Methods of Inactivation 24\u003c\/p\u003e \u003cp\u003e3.4 Evaluation of Inactivation Efficacy 28\u003c\/p\u003e \u003cp\u003e3.5 Measures of Efficacy for Inactivated Vaccines 28\u003c\/p\u003e \u003cp\u003e3.6 Mechanisms of Vaccine Protection 29\u003c\/p\u003e \u003cp\u003e3.7 Antibodies as Correlates of Protective Immunity 29\u003c\/p\u003e \u003cp\u003e3.8 Antigen Dose as Correlate of Protective Immunity 30\u003c\/p\u003e \u003cp\u003eReferences 30\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Replicating Vaccines 33\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eCraig A. Shoemaker and Phillip H. Klesius\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 33\u003c\/p\u003e \u003cp\u003e4.2 Attenuation Strategies – Bacterial Vaccines 34\u003c\/p\u003e \u003cp\u003e4.3 Attenuation Strategies – Viral Vaccines 38\u003c\/p\u003e \u003cp\u003e4.4 Induction of Immunity 39\u003c\/p\u003e \u003cp\u003e4.5 Vaccine Delivery 41\u003c\/p\u003e \u003cp\u003e4.6 Vaccine Safety Considerations 41\u003c\/p\u003e \u003cp\u003e4.7 Acknowledgement 41\u003c\/p\u003e \u003cp\u003eReferences 42\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 DNA Vaccines 47\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eEirik Biering and Kira Salonius\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 47\u003c\/p\u003e \u003cp\u003e5.2 Comparison of DNA Vaccines with Conventional Inactivated Products: Advantages and Disadvantages 48\u003c\/p\u003e \u003cp\u003e5.3 DNA Vaccines for Veterinary Use 51\u003c\/p\u003e \u003cp\u003e5.4 Biosecurity and Regulatory Considerations 52\u003c\/p\u003e \u003cp\u003eReferences 54\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Mucosal Vaccination of Fish 56\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJan H.W.M. Rombout and Viswanath Kiron\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 56\u003c\/p\u003e \u003cp\u003e6.2 History of “Mucosal” Vaccination 57\u003c\/p\u003e \u003cp\u003e6.3 Mucosal versus Systemic Immunity in Fish 58\u003c\/p\u003e \u003cp\u003e6.4 Immersion Vaccination 59\u003c\/p\u003e \u003cp\u003e6.5 Oral Vaccination 60\u003c\/p\u003e \u003cp\u003e6.6 Perspectives 64\u003c\/p\u003e \u003cp\u003eReferences 64\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Adjuvants in Fish Vaccines 68\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eCarolina Tafalla, Jarl Bøgwald, Roy A. Dalmo, Hetron Mweemba Munang’andu and Øystein Evensen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 68\u003c\/p\u003e \u003cp\u003e7.2 Vaccine Formulations 69\u003c\/p\u003e \u003cp\u003e7.3 Principles of Adjuvant Actions 70\u003c\/p\u003e \u003cp\u003e7.4 Antigenic Component 70\u003c\/p\u003e \u003cp\u003e7.5 Adjuvants 71\u003c\/p\u003e \u003cp\u003e7.6 Antigen Delivery Systems 71\u003c\/p\u003e \u003cp\u003e7.7 Delivery Vehicles 71\u003c\/p\u003e \u003cp\u003e7.8 Emulsion Vaccines 72\u003c\/p\u003e \u003cp\u003e7.9 Biodegradable Particulate Delivery Systems 74\u003c\/p\u003e \u003cp\u003e7.10 Fusion Protein Delivery System 74\u003c\/p\u003e \u003cp\u003e7.11 Immunomodulators 75\u003c\/p\u003e \u003cp\u003e7.12 Stabilizers 81\u003c\/p\u003e \u003cp\u003e7.13 Concluding Remarks and Perspectives 81\u003c\/p\u003e \u003cp\u003e7.14 Acknowledgements 81\u003c\/p\u003e \u003cp\u003eReferences 81\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 The Innate Immune Response in Fish 85\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJorunn B. Jørgensen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 85\u003c\/p\u003e \u003cp\u003e8.2 Innate Immunity: A \u003ci\u003eSensing \u003c\/i\u003eand an \u003ci\u003eEffector \u003c\/i\u003eArm 86\u003c\/p\u003e \u003cp\u003e8.3 Professional Phagocytes: The Macrophages and the Neutrophilic Granulocytes 86\u003c\/p\u003e \u003cp\u003e8.4 Natural Killer (NK)-Like Cells 88\u003c\/p\u003e \u003cp\u003e8.5 The Sensing Arm of Innate Immunity 88\u003c\/p\u003e \u003cp\u003e8.6 TLRs are the Best Studied PRRS in Fish 89\u003c\/p\u003e \u003cp\u003e8.7 NOD-Like and RIG-I Receptors are Found in Fish 90\u003c\/p\u003e \u003cp\u003e8.8 Lectins are Multifunctional Sensor Molecules for Carbohydrate Ligands 91\u003c\/p\u003e \u003cp\u003e8.9 PRRs and the Induction of Immunity 92\u003c\/p\u003e \u003cp\u003e8.10 Cytokines in Innate Immunity 92\u003c\/p\u003e \u003cp\u003e8.11 Interferons 94\u003c\/p\u003e \u003cp\u003e8.12 The Complement System 95\u003c\/p\u003e \u003cp\u003e8.13 Concluding Remarks and Perspectives 97\u003c\/p\u003e \u003cp\u003eReferences 97\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 The Adaptive Immune Response in Fish 104\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eStephen Mutoloki, Jorunn B. Jørgensen and Øystein Evensen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 105\u003c\/p\u003e \u003cp\u003e9.2 Lymphocytes are the Key Cells of the Adaptive Immune System 106\u003c\/p\u003e \u003cp\u003e9.3 Antigen Trapping and Activation of the Lymphocytes 106\u003c\/p\u003e \u003cp\u003e9.4 Antigen Presenting Cells (APCS) of Myeloid Origin 107\u003c\/p\u003e \u003cp\u003e9.5 Immunoglobulins and B Lymphocytes 108\u003c\/p\u003e \u003cp\u003e9.6 T Lymphocytes 110\u003c\/p\u003e \u003cp\u003e9.7 Cytotoxic T-Cells 111\u003c\/p\u003e \u003cp\u003e9.8 Helper T-Cells 111\u003c\/p\u003e \u003cp\u003eReferences 113\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Development, Production and Control of Fish Vaccines 116\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDag Knappskog, Joseph Koumans, Inger Kvitvang, Arne Marius Fiskum \u003c\/i\u003e\u003ci\u003eand Rune Wiulsrød\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 116\u003c\/p\u003e \u003cp\u003e10.2 Manufacturing License 117\u003c\/p\u003e \u003cp\u003e10.3 Vaccine Development 121\u003c\/p\u003e \u003cp\u003e10.4 Development of Tests 122\u003c\/p\u003e \u003cp\u003e10.5 Transfers 123\u003c\/p\u003e \u003cp\u003e10.6 Manufacturing 124\u003c\/p\u003e \u003cp\u003eReferences 127\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Legal Requirements and Authorization of Fish Vaccines 128\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAnja Holm, Byron E. Rippke and Ken Noda\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 128\u003c\/p\u003e \u003cp\u003e11.2 Manufacturer Authorization 128\u003c\/p\u003e \u003cp\u003e11.3 Food Safety – Maximum Residue Limits 131\u003c\/p\u003e \u003cp\u003e11.4 Genetically Modified Organisms 131\u003c\/p\u003e \u003cp\u003e11.5 DNA Vaccines 132\u003c\/p\u003e \u003cp\u003e11.6 Prohibition of Use of Certain Vaccines 132\u003c\/p\u003e \u003cp\u003e11.7 Use of Vaccines that are not Authorized 132\u003c\/p\u003e \u003cp\u003e11.8 Autogenous Vaccines 133\u003c\/p\u003e \u003cp\u003e11.9 Regional Rules and Competent Authorities 133\u003c\/p\u003e \u003cp\u003e11.10 The European Union and Connected EEA Countries 133\u003c\/p\u003e \u003cp\u003e11.11 United States of America 135\u003c\/p\u003e \u003cp\u003e11.12 Japan 137\u003c\/p\u003e \u003cp\u003e11.13 Other Relevant Organizations: OIE, FAO, WHO 138\u003c\/p\u003e \u003cp\u003eReferences 138\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Vaccination Strategies and Procedures 140\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAtle Lillehaug\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 141\u003c\/p\u003e \u003cp\u003e12.2 Timing of Vaccination 141\u003c\/p\u003e \u003cp\u003e12.3 Water Temperature 142\u003c\/p\u003e \u003cp\u003e12.4 Size of Fish 142\u003c\/p\u003e \u003cp\u003e12.5 Vaccination Methods 143\u003c\/p\u003e \u003cp\u003e12.6 Time for Protection to Develop – Duration of Protection 148\u003c\/p\u003e \u003cp\u003e12.7 Booster Vaccination 149\u003c\/p\u003e \u003cp\u003e12.8 Vaccination Economy 150\u003c\/p\u003e \u003cp\u003eReferences 150\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Side-Effects of Vaccination 153\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eTrygve T. Poppe and Erling O. Koppang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 153\u003c\/p\u003e \u003cp\u003e13.2 Acute Side-Effects 154\u003c\/p\u003e \u003cp\u003e13.3 Chronic Side-Effects 155\u003c\/p\u003e \u003cp\u003e13.4 Injection Site Reactions 155\u003c\/p\u003e \u003cp\u003e13.5 Extensive Abdominal Lesions 156\u003c\/p\u003e \u003cp\u003e13.6 Lesions in Other Organs 158\u003c\/p\u003e \u003cp\u003e13.7 Skeletal Lesions 159\u003c\/p\u003e \u003cp\u003e13.8 Autoimmunity 159\u003c\/p\u003e \u003cp\u003e13.9 Lesions in Non-Salmonid Species 159\u003c\/p\u003e \u003cp\u003eReferences 160\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Future Fish Vaccinology 162\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eØystein Evensen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Molecular Technologies 162\u003c\/p\u003e \u003cp\u003e14.2 Recombinant Vaccines 163\u003c\/p\u003e \u003cp\u003e14.3 Marker Vaccines 166\u003c\/p\u003e \u003cp\u003e14.4 Mucosal Vaccination 166\u003c\/p\u003e \u003cp\u003e14.5 Vaccines Against Parasitic Diseases 167\u003c\/p\u003e \u003cp\u003e14.6 Vaccines for Controlling Reproduction 167\u003c\/p\u003e \u003cp\u003e14.7 Improved Formulations 168\u003c\/p\u003e \u003cp\u003e14.8 Immunomodulation 168\u003c\/p\u003e \u003cp\u003e14.9 Cytokines and DAMPS (Danger-Associated Molecular Pattern) as Adjuvants 169\u003c\/p\u003e \u003cp\u003e14.10 Concluding Remarks 169\u003c\/p\u003e \u003cp\u003eReferences 170\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Vaccination against Vibriosis 172\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDuncan J. Colquhoun and Atle Lillehaug\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Vibriosis 172\u003c\/p\u003e \u003cp\u003e15.2 Occurrence and Significance 173\u003c\/p\u003e \u003cp\u003e15.3 Etiology 174\u003c\/p\u003e \u003cp\u003e15.4 Pathogenesis 176\u003c\/p\u003e \u003cp\u003e15.5 Vaccines 177\u003c\/p\u003e \u003cp\u003e15.6 Vaccination Procedures 179\u003c\/p\u003e \u003cp\u003e15.7 Vaccine Effect 179\u003c\/p\u003e \u003cp\u003e15.8 Side-Effects 180\u003c\/p\u003e \u003cp\u003e15.9 Regulations 180\u003c\/p\u003e \u003cp\u003eReferences 181\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Vaccination against Furunculosis 185\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePaul J. Midtlyng\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 185\u003c\/p\u003e \u003cp\u003e16.2 Occurrence and Significance 186\u003c\/p\u003e \u003cp\u003e16.3 Etiology 187\u003c\/p\u003e \u003cp\u003e16.4 Pathogenesis and Virulence 187\u003c\/p\u003e \u003cp\u003e16.5 Antigens 189\u003c\/p\u003e \u003cp\u003e16.6 Vaccines 189\u003c\/p\u003e \u003cp\u003e16.7 Vaccination Procedures 190\u003c\/p\u003e \u003cp\u003e16.8 Effects 191\u003c\/p\u003e \u003cp\u003e16.9 Side-Effects 192\u003c\/p\u003e \u003cp\u003e16.10 Vaccination Against Atypical Furunculosis 192\u003c\/p\u003e \u003cp\u003e16.11 Legal Aspects and Regulations 193\u003c\/p\u003e \u003cp\u003eReferences 194\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Vaccination against Photobacteriosis 200\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJes\u003c\/i\u003e\u003ci\u003eú\u003c\/i\u003e\u003ci\u003es L. Romalde\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Occurrence and Significance 200\u003c\/p\u003e \u003cp\u003e17.2 Etiology 202\u003c\/p\u003e \u003cp\u003e17.3 Pathogenesis 202\u003c\/p\u003e \u003cp\u003e17.4 Vaccines 204\u003c\/p\u003e \u003cp\u003e17.5 Vaccination Procedures 205\u003c\/p\u003e \u003cp\u003e17.6 Effect 206\u003c\/p\u003e \u003cp\u003e17.7 Side-Effects 206\u003c\/p\u003e \u003cp\u003e17.8 Regulations 207\u003c\/p\u003e \u003cp\u003eReferences 207\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Vaccination against Enteric Septicemia of Catfish 211\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePhillip H. Klesius and Julia W. Pridgeon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Significance 211\u003c\/p\u003e \u003cp\u003e18.2 Occurrence 212\u003c\/p\u003e \u003cp\u003e18.3 Etiology 212\u003c\/p\u003e \u003cp\u003e18.4 Pathogenesis 213\u003c\/p\u003e \u003cp\u003e18.5 Virulence Factors 214\u003c\/p\u003e \u003cp\u003e18.6 Vaccines and Immunity 214\u003c\/p\u003e \u003cp\u003e18.7 Regulations (US) 220\u003c\/p\u003e \u003cp\u003e18.8 Vaccination Practices 220\u003c\/p\u003e \u003cp\u003eReferences 221\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Vaccination against Yersiniosis 226\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAndrew Bridle and Barbara Nowak\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19.1 Yersiniosis 226\u003c\/p\u003e \u003cp\u003e19.2 Occurrence and Significance 227\u003c\/p\u003e \u003cp\u003e19.3 Etiology 227\u003c\/p\u003e \u003cp\u003e19.4 Pathogenesis 228\u003c\/p\u003e \u003cp\u003e19.5 Vaccines 229\u003c\/p\u003e \u003cp\u003e19.6 Vaccination Procedures 230\u003c\/p\u003e \u003cp\u003e19.7 Vaccine Effect 231\u003c\/p\u003e \u003cp\u003e19.8 Side-Effects 232\u003c\/p\u003e \u003cp\u003e19.9 Regulations 232\u003c\/p\u003e \u003cp\u003eReferences 233\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Vaccination against Streptococcosis and Lactococcosis 236\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJulia W. Pridgeon and Phillip H. Klesius\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20.1 Occurrence 236\u003c\/p\u003e \u003cp\u003e20.2 Significance 236\u003c\/p\u003e \u003cp\u003e20.3 Etiology 237\u003c\/p\u003e \u003cp\u003e20.4 Pathogenesis 238\u003c\/p\u003e \u003cp\u003e20.5 Vaccines 239\u003c\/p\u003e \u003cp\u003e20.6 Vaccination Procedures and Vaccine Effect 240\u003c\/p\u003e \u003cp\u003e20.7 Side-Effects 242\u003c\/p\u003e \u003cp\u003e20.8 Regulations 242\u003c\/p\u003e \u003cp\u003eReferences 243\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Vaccination against Piscirickettsiosis 246\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSergio H. Marshall and Jaime A. Tobar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21.1 Occurrence and Significance 246\u003c\/p\u003e \u003cp\u003e21.2 Etiology 247\u003c\/p\u003e \u003cp\u003e21.3 Pathogenesis 248\u003c\/p\u003e \u003cp\u003e21.4 Vaccines and Vaccination 248\u003c\/p\u003e \u003cp\u003e21.5 Current Vaccine Status 249\u003c\/p\u003e \u003cp\u003e21.6 Future Perspectives 251\u003c\/p\u003e \u003cp\u003eReferences 252\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Vaccination against Bacterial Kidney Disease 255\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDiane G. Elliott, Gregory D. Wiens, K. Larry Hammell and Linda D. Rhodes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22.1 Introduction 255\u003c\/p\u003e \u003cp\u003e22.2 Occurrence 256\u003c\/p\u003e \u003cp\u003e22.3 Significance 256\u003c\/p\u003e \u003cp\u003e22.4 Etiology 257\u003c\/p\u003e \u003cp\u003e22.5 Pathogenesis 259\u003c\/p\u003e \u003cp\u003e22.6 Vaccines 260\u003c\/p\u003e \u003cp\u003e22.7 Vaccination Procedures 261\u003c\/p\u003e \u003cp\u003e22.8 Vaccine Effects and Side-Effects 262\u003c\/p\u003e \u003cp\u003e22.9 Regulations 264\u003c\/p\u003e \u003cp\u003e22.10 Future Directions 264\u003c\/p\u003e \u003cp\u003eReferences 266\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Vaccination against Diseases Caused by \u003ci\u003eFlavobacteriaceae \u003c\/i\u003eSpecies 273\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eKrister Sundell, Eva Högfors-Rönnholm and Tom Wiklund\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23.1 Introduction 273\u003c\/p\u003e \u003cp\u003e23.2 Bacterial Gill Disease (\u003ci\u003eFlavobacterium branchiophilum\u003c\/i\u003e) 274\u003c\/p\u003e \u003cp\u003e23.3 Columnaris Disease (\u003ci\u003eFlavobacterium columnare\u003c\/i\u003e) 275\u003c\/p\u003e \u003cp\u003e23.4 Bacterial Cold-Water Disease (\u003ci\u003eFlavobacterium psychrophilum\u003c\/i\u003e) 278\u003c\/p\u003e \u003cp\u003e23.5 Tenacibaculosis (\u003ci\u003eTenacibaculum maritimum\u003c\/i\u003e) 281\u003c\/p\u003e \u003cp\u003eReferences 282\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 Vaccination against Viral Hemorrhagic Septicemia and Infectious Hematopoietic Necrosis 289\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSt\u003c\/i\u003e\u003ci\u003eé\u003c\/i\u003e\u003ci\u003ephane Biacchesi and Michel Br\u003c\/i\u003e\u003ci\u003eé\u003c\/i\u003e\u003ci\u003emont\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24.1 Occurrence and Significance 289\u003c\/p\u003e \u003cp\u003e24.2 Etiology 291\u003c\/p\u003e \u003cp\u003e24.3 Pathogenesis 292\u003c\/p\u003e \u003cp\u003e24.4 Vaccines 293\u003c\/p\u003e \u003cp\u003e24.5 Concluding Remarks 297\u003c\/p\u003e \u003cp\u003e24.6 Acknowledgements 297\u003c\/p\u003e \u003cp\u003eReferences 298\u003c\/p\u003e \u003cp\u003e\u003cb\u003e25 Vaccination against Infectious Pancreatic Necrosis 303\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eEspen Rimstad\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25.1 Occurrence and Significance 303\u003c\/p\u003e \u003cp\u003e25.2 Etiology 305\u003c\/p\u003e \u003cp\u003e25.3 Pathogenesis 306\u003c\/p\u003e \u003cp\u003e25.4 Vaccines and Vaccine Effect 306\u003c\/p\u003e \u003cp\u003e25.5 Vaccine-Induced Immune Responses 309\u003c\/p\u003e \u003cp\u003e25.6 Regulations 309\u003c\/p\u003e \u003cp\u003eReferences 309\u003c\/p\u003e \u003cp\u003e\u003cb\u003e26 Vaccination against Infectious Salmon Anemia 313\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eKnut Falk\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26.1 Occurrence and Significance 313\u003c\/p\u003e \u003cp\u003e26.2 Etiology 314\u003c\/p\u003e \u003cp\u003e26.3 Pathogenesis 315\u003c\/p\u003e \u003cp\u003e26.4 Vaccines 316\u003c\/p\u003e \u003cp\u003e26.5 Regulatory Issues 317\u003c\/p\u003e \u003cp\u003eReferences 318\u003c\/p\u003e \u003cp\u003e\u003cb\u003e27 Vaccination against Koi Herpesvirus Disease 321\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eArnon Dishon, Ofer Ashoulin, E. Scott Weber III and Moshe Kotler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27.1 Occurrence and Significance 321\u003c\/p\u003e \u003cp\u003e27.2 Etiology 322\u003c\/p\u003e \u003cp\u003e27.3 Pathogenesis 323\u003c\/p\u003e \u003cp\u003e27.4 Vaccine and Vaccination 324\u003c\/p\u003e \u003cp\u003e27.5 Efficacy 327\u003c\/p\u003e \u003cp\u003e27.6 Safety 329\u003c\/p\u003e \u003cp\u003e27.7 Regulatory Issues 330\u003c\/p\u003e \u003cp\u003eReferences 330\u003c\/p\u003e \u003cp\u003e\u003cb\u003e28 Vaccination against Diseases Caused by \u003ci\u003eSalmonid alphavirus \u003c\/i\u003e334\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eEmilie M\u003c\/i\u003e\u003ci\u003eé\u003c\/i\u003e\u003ci\u003erour and Michel Br\u003c\/i\u003e\u003ci\u003eé\u003c\/i\u003e\u003ci\u003emont\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28.1 Occurrence and Significance 334\u003c\/p\u003e \u003cp\u003e28.2 Etiology 335\u003c\/p\u003e \u003cp\u003e28.3 Pathogenesis 338\u003c\/p\u003e \u003cp\u003e28.4 Immunity and Vaccine Development 338\u003c\/p\u003e \u003cp\u003eReferences 339\u003c\/p\u003e \u003cp\u003e\u003cb\u003e29 Vaccination against Diseases Caused by \u003ci\u003eBetanodavirus \u003c\/i\u003e341\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSonal Patel and Audun H. Nerland\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29.1 Viral Encephalopathy and Retinopathy (VER) 341\u003c\/p\u003e \u003cp\u003e29.2 Occurrence and Significance 342\u003c\/p\u003e \u003cp\u003e29.3 Etiology 342\u003c\/p\u003e \u003cp\u003e29.4 Pathogenesis 343\u003c\/p\u003e \u003cp\u003e29.5 Immune Status and Response to NNV 344\u003c\/p\u003e \u003cp\u003e29.6 Vaccines 344\u003c\/p\u003e \u003cp\u003e29.7 Replicating Vaccines 345\u003c\/p\u003e \u003cp\u003e29.8 Inactivated Virus 347\u003c\/p\u003e \u003cp\u003e29.9 Recombinant Protein\/Peptide 347\u003c\/p\u003e \u003cp\u003e29.10 DNA Vaccines 348\u003c\/p\u003e \u003cp\u003e29.11 Future Prospects and Recommendations 349\u003c\/p\u003e \u003cp\u003eReferences 349\u003c\/p\u003e \u003cp\u003e\u003cb\u003e30 Immunostimulation of Crustaceans 352\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eIndrani Karunasagar, Singaiah NaveenKumar, Biswajit Maiti and Praveen Rai\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30.1 Introduction 352\u003c\/p\u003e \u003cp\u003e30.2 Immune System of Crustaceans 353\u003c\/p\u003e \u003cp\u003e30.3 Immunostimulants of Crustaceans 361\u003c\/p\u003e \u003cp\u003e30.4 Acknowledgements 366\u003c\/p\u003e \u003cp\u003eReferences 366\u003c\/p\u003e \u003cp\u003eIndex 373\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Agriculture \u0026amp; farming [\u003ca title=\"See our other books on Agriculture \u0026amp; farming\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Agriculture%20\u0026amp;%20farming%20%5BTV%5D%22\"\u003eTV\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Brand New","offer_id":52278019916056,"sku":"9780470674550","price":128.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470674550_e792fdac-587c-4526-a825-7ecbfcc5161d.jpg?v=1781455794","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/fish-vaccination-hardback-9780470674551","provider":"Freshly Printed Books","version":"1.0","type":"link"}